Patient and Lesion Characteristics for Stool Study.

<p>Abbreviation: –, not applicable.</p><p>^a Cases comprised patients with at least one SSP (sessile serrated polyp) ≥1 cm found on screening or surveillance colonoscopy and without synchronous advanced adenomas or CRC.</p><p>^b Control patients had no pathology (no CRC, colorectal polyps, hemorrhagic lesions, or inflammation) on screening or surveillance colonoscopy.</p><p>^c Right-sided location was defined as proximal to the splenic flexure.</p><p>^d Patients found to harbor synchronous polyps (adenomatous or serrated) <1 cm in size were included as cases.</p

Tissue levels of aberrantly methylated genes.

<p>Tissue levels of methylated <i>BMP3 (mBMP3)</i> and <i>NDRG4 (mNDRG4)</i> genes are compared in normal colorectal mucosa, n = 20 unique control patients, and sessile serrated polyps (SSP), n = 20 unique case patients. Marker levels are normalized to <i>β-actin</i> (a marker of total human DNA) and expressed in relative units. Levels were substantially and significantly higher in SSP than normal colon for both <i>mBMP3</i> (p<0.0001) and <i>mNDRG4</i> (p<0.0001).</p

Detection of SSP by stool assay of <i>mBMP3</i> and by fecal immunochemical testing (FIT).

<p>FIT sensitivity was evaluated at the conventional cutoff of 100/ml buffer (FIT-100) and at 50 ng/ml (FIT-50). Specificity cutoffs for stool DNA marker <i>mBMP3</i> were selected to match those for both FIT-100 and FIT-50 so that sensitivities could be most meaningfully compared.</p